Cellid, Co., Ltd. (KOSDAQ:299660)
South Korea · Delayed Price · Currency is KRW 2,780.00
-70.00 (-2.46%)
At close: Feb 27, 2026
Cellid, Revenue
In the year 2024, Cellid, had annual revenue of 4.17B KRW. Cellid, had revenue of 1.88B in the quarter ending December 31, 2024.
Revenue
4.17B
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
82.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.17B | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 480.00M | -429.09M | -47.20% |
| Dec 31, 2021 | 909.09M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| PharmGen Science | 171.66B |
| Yuyu Pharma | 139.51B |
| Ray Co., Ltd. | 97.57B |
| Enzychem Lifesciences | 72.17B |